エピソード

  • Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease
    2025/05/01
    In this episode, we are joined by entrepreneur and television personality, Barbara Corcoran. While many know Barbara for her business acumen and dynamic presence on Shark Tank, fewer may know the deeply personal and powerful story she shares today—her nine-year journey as a caregiver for her mother, who lived with Alzheimer disease. In this heartfelt conversation, Barbara opens up about the early signs her family overlooked, the emotional toll of watching her mother's personality shift, and the pivotal moment that changed their approach to caregiving. From practical strategies to navigate agitation in Alzheimer disease, to profound lessons in empathy, patience, and family dynamics, Barbara’s story offers inspiration and wisdom for caregivers and physicians. For more information, please visit www.RecognizeAlzheimersAgitation.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    18 分
  • Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test
    2025/03/21
    Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    21 分
  • Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group
    2025/02/25
    Nicolas Villain, MD, PhD, Associate Professor of Neurology, Sorbonne University, Paris, France, discusses the International Working Group’s updated diagnostic criteria for the diagnosis and staging of Alzheimer disease, which offer an alternative definitional view of AD as a clinical-biologic construct. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    12 分
  • Blarcamesine: An Investigational Oral Drug for Alzheimer Disease
    2025/01/25
    Timo Grimmer, MD, Associate Professor of Psychiatry and Psychotherapy and Head of the Centre for Cognitive Disorders at the Technical University of Munich, Germany, discusses the experimental oral small molecule drug blarcamesine, which is under investigation as a potential treatment for Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    16 分
  • The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers
    2024/12/19
    Sarena Ho, Health Insurance Specialist at the CMS Innovation Center, provides an overview on the Guiding an Improved Dementia Experience (GUIDE) Model, which helps physicians provide coordinated care to support patients with dementia and their caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    11 分
  • The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease
    2024/11/19
    Gary E. Gibson, PhD, Professor of Neurosciences, Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, details his research related to metabolic changes associated with Alzheimer disease and a clinical trial studying the effects of benfotiamine therapy on cognitive and other outcomes. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    16 分
  • BrainCheck as a Digital Cognitive Assessment Tool
    2024/11/08
    Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    7 分
  • Kramer, Van Dyck
    2024/09/27
    Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    12 分